about
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.The role of inflammation in inflammatory breast cancer.Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosisCirculating tumor cells in newly diagnosed inflammatory breast cancer.Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast CancerHigh HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally AdvEpidemiological risk factors associated with inflammatory breast cancer subtypes.Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.Survival of patients with metastatic breast cancer with or without locoregional therapy.Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patientsErratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosisDifferences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based studyClinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancersEarly skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer
P50
Q27853194-1DAB6258-3659-40F9-BFDC-EBE76AA3D6C1Q34392877-4D5B5C1F-AB56-4120-8A92-24C2137270FCQ34419629-E0662ED1-3561-4568-9354-5D11B7F2E17FQ34478105-775BCC4D-F5A7-4E29-BC6A-8819E0FE9BBFQ35052773-B7CA1873-DDA8-4397-9B72-660DF3667224Q35148075-84A99BCC-D4B8-4781-A593-B4B52D8534BCQ36452222-05F4ED50-E728-4DEA-A2DF-94B344F2FB02Q36652833-B6EE3B6A-93DF-44A3-9402-7F989E2814CCQ37015722-08F3FD7F-B8FC-478A-A275-3A22BE1A1A3DQ39214862-3A25BFC7-4EB7-4427-9EB1-E08FFC8DE4D2Q40887298-59030E10-E5DC-482F-ACE5-B400EF8C12EEQ46399001-264F43E2-F536-4FFD-A846-C7BA9A72B3C1Q57578864-59983095-A2C5-4C16-AC43-75C32FDACDE6Q63366153-BA4EF0FD-8B19-4EDA-8E77-1FE2EA6BA3AFQ84567940-7E4C9DCD-6285-4A90-9F65-B2D32087D2EBQ85640592-DDC51BC8-D4D7-49D6-969A-4592918B9083Q87947624-0A71E444-64B7-4007-BCD5-A7D7E72A53D4
P50
description
researcher ORCID ID = 0000-0002-4168-5275
@en
wetenschapper
@nl
name
Tamer M Fouad
@ast
Tamer M Fouad
@en
Tamer M Fouad
@es
Tamer M Fouad
@nl
type
label
Tamer M Fouad
@ast
Tamer M Fouad
@en
Tamer M Fouad
@es
Tamer M Fouad
@nl
prefLabel
Tamer M Fouad
@ast
Tamer M Fouad
@en
Tamer M Fouad
@es
Tamer M Fouad
@nl
P1153
26221618600
P31
P496
0000-0002-4168-5275